Taiwan Three Mast Fails to Meet ‘Fundamental cGMPs,’ Warning States
Taiwan Three Mast Pharmaceutical is holding an FDA warning letter after falling short of “fundamental cGMPs,” the FDA says.
For example, the company did not test raw materials and finished drug products, used unvalidated manufacturing processes and lacked basic cGMP training at its facility, according to the Dec. 17 warning letter posted recently online.
The company did not test incoming lots of menthol and methyl salicylate APIs prior to their use in production, instead relying solely on suppliers’ certificates of analysis. Further, it had not established assay methods to determine the strength of these ingredients in its finished drug products. Taiwan Three Mast only identified these ingredients by thin layer chromatography, the letter notes.
The hard fact is, you can’t be on the manufacturing floor, in the labs or control rooms where people face the decisions that will test their training. But you can give them the reinforcement they need to make the right decisions with FDAnews’ six-lesson DVD employee training package Focus on GxPs: A DVD Training Toolkit for Your Most Common and Costly Manufacturing Mistakes.
This six-disc package includes six modules, along with leader discussion guides, illustrating six of the most common mistakes that lead to ruined batches, recalls or worse. Each 10- to 12-minute scenario shows how and why human errors occur, and reinforces the proper way to handle each situation. Don’t miss your opportunity, order your copy today!